Can researchers prove where a localized therapy acts—and whether that location changes its effect?

In separate mouse systems, engineered bacteria, vaccination against tumor vasculature, and CAR T cells that secrete a VIP-receptor antagonist altered local immune biology or antitumor activity. In rat nerve-root injury, two peptide-loaded hydrogels paired local placement with neural, neuromuscular, and movement endpoints; the NEP1-40 study included blank-material and free-peptide arms, while the newer dual-network study combined several potentially active features without equivalent component comparisons in the available abstract. These approaches use different targets, materials, and models and are not interchangeable.

A localized system can appear active without showing whether location, cargo, carrier, or their interaction produced the effect. Closing that gap would make later development decisions more auditable.

Matched local-versus-systemic comparisons where relevant, component-removal controls for multifunctional materials, concentration and persistence measurements, direct target-engagement evidence, off-target assessment, and validation in human tissue or clinical studies.